Bio-Techne TECH R&D
R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Techne's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Techne's R&D?
- Bio-Techne (TECH) reported R&D of $23.46M in Q1 2026.
- How has Bio-Techne's R&D changed year-over-year?
- Bio-Techne's R&D decreased by 4.6% year-over-year, from $24.58M to $23.46M.
- What is the long-term trend for Bio-Techne's R&D?
- Over 3 years (2022 to 2025), Bio-Techne's R&D has grown at a 4.5% compound annual growth rate (CAGR), from $87.14M to $99.5M.
- What does R&D mean?
- The money spent on creating new products or improving existing technologies.
- How do you interpret R&D?
- Higher spending signals a commitment to innovation and long-term growth, though it may temporarily reduce current profitability.
- How does R&D compare across companies?
- High R&D intensity is a hallmark of the life sciences and biotech sector compared to traditional manufacturing.